AbbVie Inc. $ABBV Stock: Raleigh Capital Management Inc. Decreases Stake

Raleigh Capital Management Inc. decreased its stake in shares of AbbVie Inc. (NYSE:ABBV) by 21.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 14,297 shares of the company’s stock after selling 3,794 shares during the period. AbbVie accounts for about 1.2% of Raleigh Capital Management Inc.’s holdings, making the stock its 12th largest position. Raleigh Capital Management Inc.’s holdings in AbbVie were worth $3,740,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in ABBV. Lifelong Wealth Advisors Inc. boosted its position in AbbVie by 2.1% during the third quarter. Lifelong Wealth Advisors Inc. now owns 1,755 shares of the company’s stock worth $459,000 after purchasing an additional 36 shares during the period. IMG Wealth Management Inc. boosted its holdings in shares of AbbVie by 22.8% during the 3rd quarter. IMG Wealth Management Inc. now owns 194 shares of the company’s stock worth $51,000 after buying an additional 36 shares during the period. Foundry Financial Group Inc. grew its stake in AbbVie by 4.6% in the 3rd quarter. Foundry Financial Group Inc. now owns 839 shares of the company’s stock valued at $219,000 after buying an additional 37 shares during the last quarter. James T. Borello RIA raised its holdings in AbbVie by 3.5% in the 3rd quarter. James T. Borello RIA now owns 1,192 shares of the company’s stock worth $312,000 after acquiring an additional 40 shares during the period. Finally, ACT Advisors LLC. lifted its position in AbbVie by 2.5% during the 2nd quarter. ACT Advisors LLC. now owns 1,688 shares of the company’s stock worth $425,000 after acquiring an additional 41 shares during the last quarter. 70.23% of the stock is owned by institutional investors.

Insider Activity

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at approximately $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Corporate insiders own 0.06% of the company’s stock.

AbbVie Stock Performance

NYSE ABBV opened at $294.80 on Friday. The firm has a 50-day simple moving average of $269.35 and a 200 day simple moving average of $237.23. AbbVie Inc. has a twelve month low of $190.75 and a twelve month high of $298.74. The stock has a market cap of $520.85 billion, a PE ratio of 83.28, a PEG ratio of 1.33 and a beta of 0.24.

AbbVie (NYSE:ABBV) last issued its quarterly earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%. The firm had revenue of $17.40 billion for the quarter, compared to analyst estimates of $17.32 billion. During the same period in the previous year, the company posted $1.86 earnings per share. The company’s quarterly revenue was up 10.3% compared to the same quarter last year. Research analysts forecast that AbbVie Inc. will post 13.92 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 2.3%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is presently 195.48%.

AbbVie News Roundup

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Q3 results beat expectations. Adjusted earnings per share were $3.82 versus the $3.73 analyst consensus, while revenue rose 10.3% year over year to $17.404 billion, ahead of the $17.32 billion estimate. Adjusted EPS more than doubled from the prior-year quarter. AbbVie Reports Third-Quarter 2026 Financial Results
• Positive Sentiment: Immunology and neuroscience provided strong momentum. Skyrizi generated $5.776 billion in revenue and Rinvoq produced $2.706 billion, helping immunology revenue increase 16.3%. Neuroscience revenue climbed 19.4%, led by Vraylar, therapeutic Botox, Ubrelvy and Qulipta. AbbVie Lifts 2026 Outlook as Immunology, Neuroscience Quarterly Sales Beat Views
• Positive Sentiment: Management raised guidance and its dividend. AbbVie increased its 2026 adjusted EPS outlook to $13.95–$13.99 from $13.76–$13.96, despite including $0.69 per share of year-to-date acquired in-process research and development and milestone expenses. The company also announced a 5.2% dividend increase beginning with the February 2027 payment. AbbVie Raises FY26 Adjusted EPS Outlook and Boosts Dividend
• Positive Sentiment: Pipeline expansion supports longer-term confidence. AbbVie completed its acquisition of Apogee Therapeutics, strengthening its immunology pipeline, while Qulipta also outperformed topiramate in a Phase 3 migraine-prevention study. AbbVie QULIPTA Phase 3 Migraine Prevention Trial
• Negative Sentiment: Investors remain focused on valuation and concentration risks. Humira revenue fell 31.2% to $683 million, while aesthetics revenue declined 1.4%. After a substantial multiyear rally and trading near its 52-week high, analysts question whether additional valuation expansion is justified and how effectively AbbVie can sustain growth beyond Skyrizi and Rinvoq. Skyrizi and Rinvoq Dominate AbbVie Q3

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on ABBV. Wolfe Research upgraded shares of AbbVie from a “peer perform” rating to an “outperform” rating and upped their price target for the company from $235.00 to $300.00 in a report on Thursday, August 13th. Rothschild & Co Redburn lifted their price objective on AbbVie from $284.00 to $285.00 and gave the stock a “buy” rating in a research note on Tuesday, August 4th. Piper Sandler boosted their price objective on AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. BNP Paribas Exane increased their target price on AbbVie from $218.00 to $247.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Finally, The Goldman Sachs Group raised their target price on AbbVie from $258.00 to $294.00 and gave the company a “neutral” rating in a report on Friday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $279.86.

About AbbVie

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.